Mucosal Immunization and Adjuvants

被引:29
|
作者
Hasegawa, Hideki [1 ]
van Reit, Elly [1 ]
Kida, Hiroshi [2 ]
机构
[1] Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Tokyo 1628640, Japan
[2] Hokkaido Univ, Res Ctr Zoonosis Control, Sapporo, Hokkaido, Japan
关键词
INFLUENZA-VIRUS INFECTION; DOUBLE-STRANDED-RNA; POLYMERIC IG RECEPTOR; DENDRITIC CELLS; ANTIBODY-RESPONSES; RESPIRATORY-TRACT; CROSS-PROTECTION; SECRETORY IGA; VACCINE PROTECTS; MONOMERIC IGA;
D O I
10.1007/82_2014_402
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The goal of the influenza vaccine is to prevent influenza virus infection and control the yearly seasonal epidemic and pandemic. However, the presently available parenteral influenza vaccine induces only systemic humoral immunity, which does not prevent influenza virus infection on the mucosal surface. Secretary IgA antibodies play an important role in preventing natural infection. Moreover, the IgA antibody response mediates cross-protection against variant viruses in animal models. Thus, a mucosal influenza vaccine that induces mucosal immunity would be a powerful tool to protect individuals from the influenza virus. Although the function of the mucosal immune system, especially in the respiratory tract, is not completely understood, there are several studies underway to develop mucosal influenza vaccines. Here, we will review current knowledge concerning the induction of IgA, the role of B-cell production of influenza virus specific IgA antibodies in anti-influenza immunity, and the role of humoral memory responses induced upon vaccination.
引用
收藏
页码:371 / 380
页数:10
相关论文
共 50 条
  • [1] Role of mucosal adjuvants in mucosal immunization
    Oliver, AR
    Elson, CO
    [J]. CURRENT OPINION IN GASTROENTEROLOGY, 1998, 14 (06) : 483 - 487
  • [2] Evaluation of TLR ligands as potential adjuvants for mucosal immunization
    Buffa, V.
    Klein, K.
    Shattock, R.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2010, 26 (10) : A38 - A38
  • [3] The rational design of vaccine adjuvants for mucosal and neonatal immunization
    Mahon, BP
    [J]. CURRENT MEDICINAL CHEMISTRY, 2001, 8 (09) : 1057 - 1075
  • [4] Antipeptide antibody responses following intranasal immunization: Effectiveness of mucosal adjuvants
    Olszewska, W
    Partidos, CD
    Steward, MW
    [J]. INFECTION AND IMMUNITY, 2000, 68 (09) : 4923 - 4929
  • [5] Evaluation of mucosal adjuvants and immunization routes for the induction of systemic and mucosal humoral immune responses in macaques
    Veazey, Ronald S.
    Siddiqui, Asna
    Klein, Katja
    Buffa, Viviana
    Fischetti, Lucia
    Doyle-Meyers, Lara
    King, Deborah F.
    Tregoning, John S.
    Shattock, Robin J.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (12) : 2913 - 2922
  • [6] Mucosal adjuvants
    Stevceva, L
    Ferrari, MG
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (06) : 801 - 811
  • [7] Mucosal Adjuvants
    Harandi, Ali M.
    Medaglini, Donata
    [J]. CURRENT HIV RESEARCH, 2010, 8 (04) : 330 - 335
  • [8] Mucosal adjuvants
    Lightowlers, M. W.
    [J]. PARASITE IMMUNOLOGY, 2006, 28 (06) : 254 - 255
  • [9] Mucosal adjuvants
    Freytag, LC
    Clements, JD
    [J]. VACCINE, 2005, 23 (15) : 1804 - 1813
  • [10] EFFECTS OF PARENTERAL IMMUNIZATION AND ADJUVANTS ON THE MUCOSAL IMMUNE-RESPONSE TO SHIGELLA-FLEXNERI
    MCDONALD, RA
    KEREN, DF
    STRUBLE, E
    [J]. FEDERATION PROCEEDINGS, 1984, 43 (03) : 379 - 379